Pulse Biosciences stock soars to lead premarket gainers after positive study results

Shares of Pulse Biosciences Inc. PLSE, +3.35%rocketed 38% in premarket trade Friday, to pace all the premarket gainers, after the company revealed positive results from a study of its treatment for skin lesions. Pulse said late Thursday that in a clinical trial of the elimination of seborrheic keratosis (SK), also known as senile warts, treatment with the the company's non-thermal Nano-Pulse Stimulation (NPS) technology showed that 82% of treated lesions were rated as clear or mostly clear after 106 days.

"These impressive results demonstrate the reliable removal of SK lesions with a single treatment using NPS technology," said said Thomas Rohrer, a dermatologic and Mohs skin cancer surgeon in Boston. The stock has tumbled 23.0% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF IBB, +1.32%has slipped 0.1% and the S&P 500 SPX, +0.83%has eased 0.4%.